LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial
Andreas Baumbach,Niels van Royen,Ignacio J Amat-Santos,Martin Hudec,Matjaz Bunc,Alexander Ijsselmuiden,Peep Laanmets,Daniel Unic,Bela Merkely,Renicus S Hermanides,Vlasis Ninios,Marcin Protasiewicz,Benno J W M Rensing,Pedro L Martin,Fausto Feres,Manuel De Sousa Almeida,Eric van Belle,Axel Linke,Alfonso Ielasi,Matteo Montorfano,Mark Webster,Konstantinos Toutouzas,Emmanuel Teiger,Francesco Bedogni,Michiel Voskuil,Manuel Pan,Oskar Angerås,Won-Keun Kim,Jürgen Rothe,Ivica Kristić,Vicente Peral,Scot Garg,Hesham Elzomor,Akihiro Tobe,Marie-Claude Morice,Yoshinobu Onuma,Osama Soliman,Patrick W Serruys,LANDMARK trial investigators,Dimytri Siqueira,Ibraim Pinto,Alberto Cervone,Jorge Assef,Andrea Vilela,Antonio Paladino,Auristela Ramos,Mariana Rezende,Samira Ghorayeb,Tacianne Rolemberg Braga Silva,Savica Gjorgjievska,Irzal Hadzibegovic,Ivana Jurin,Tomislav Sipic,Nikola Pavlovic,Igor Rudez,Sime Manola,Romain Gallet DE Saint-Aurin,Madjid Boukantar,Eroan Nicolas,Pierre Valdimir Ennezat,Jean Marie Urien,Flavien Vincent,Cedric Delhaye,Tom Denimal,Alessandro Cosenza,Thibault Pamart,Sina Porouchani,Francois Pontana,David Montaigne,Vincent Balmette,Mohamed Bechiri,Elisabeth Chen,Dany Janah,Matthias Renker,Dirk Westermann,Christian Valina,Miroslaw Ferenc,Nikolaus Löffelhardt,Faridun Rahimi,Philipp Breitbart,Kilian Franke,Martin Czerny,Nawras Diab,Peter Sick,Medea Adeishvili,Norman Mangner,Stephan Haussig,Krunuslav Sveric,Lisa Crusius,Marie Roehlig,Leonidas Koliastasis,Maria Drakopoulou,Odysseas Katsaros,Nikolaos Ktenopoulos,Andreas Ioanniadis,Sotirios Evangelou,Ilias Ninios,Levente Molnar,Roland Papp,Ferencz Arnold-Béla,Orsolya Demeterné Kiss,Andrea Nagy,Csilla Czimbalmos,Dario Pellegrinni,Carolina Montonati,Mariano Pellicano,Giulio Guagliumi,Maurizio Tespili,Bellini Barbara,Russo Filippo,Ancona Marco,Vella Ciro,Ferri Luca,Agricola Eustachio,Ingallina Giacomo,Gaspare Cannone,Nedy Brambilla,Luca Testa,Stefano Avondo,Roberto Valvo,Robin Clarke,Mandy Fish,Michal Kosowski,Magdalena Krawczyk,Piotr Kubler,Tomasz Kotwica,Rui Teles,Pedro Gonçalves,Luis Raposo,Joã Brito,Silvio Leal,Pedro Freitas,Regina Ribeiras,Petra Poliacikova,Peter Marko Mihailovic,Simon Terseglav,Klemen Steblovnik,Miha Cercek,Luka Vitez,Miha Sustersic,Ana Kovac,Polonca Kogoj,Ljupka Dimitrovska,J Raul Delgado Arana,Sandra Santos Martinez,Alfredo Redondo Dieguez,Alejandro Barrero,Esther Gonzalez-Bartol,Cristhian Aristizabal,Ana Serrador Frutos,Juan Pablo Sanchez Luna,Mario Garcia Gomez,Tania Rodriguez Gabella,Verónica Quevedo Nelson,Jose Novoa Medina,Soledad Ojeda,Javier Suarez de Lezo,Miguel Romero,Rafael Gonzalez-Manzanares,Marco Alvarado,Dolores Mesa,Jorge Perea,Petur Petursson,Monér Alchay,Sofie Andréen,Menno Van Gameren,Peter den Heijer,Martijn Meuwissen,Jin M Cheng,Jeroen Vos,B E Schölzel,C Simsek,S Hubbers,Ben J L Van den Branden,N A Stens,Gaa Versteeg,Mjp Rooijakkers,H R Gehlmann,Mwa Verkroost,Gsc Geuzebroek,M H Van Wely,R J Van Geuns,L X van Nunen,Lafm van Garsse,L Timmers,Jurrien Ten Berg,A O Kraaijeveld,M G Dickinson,T C Dessing,M M Mokhles
DOI: https://doi.org/10.1016/S0140-6736(24)00821-3
2024-06-22
Abstract:Background: Transcatheter aortic valve implantation is an established, guideline-endorsed treatment for severe aortic stenosis. Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV) series with the aortic annulus is facilitated by increasing its diameter in 1·5 mm increments, compared with the usual 3 mm increments in valve size. The LANDMARK trial aimed to show non-inferiority of the Myval THV series compared with the contemporary THVs Sapien Series (Edwards Lifesciences, Irvine, CA, USA) or Evolut Series (Medtronic, Minneapolis, MN, USA). Methods: In this prospective, multinational, randomised, open-label, non-inferiority trial across 31 hospitals in 16 countries (Germany, France, Sweden, the Netherlands, Italy, Spain, New Zealand, Portugal, Greece, Hungary, Poland, Slovakia, Slovenia, Croatia, Estonia, and Brazil), 768 participants with severe symptomatic native aortic stenosis were randomly assigned (1:1) to the Myval THV or a contemporary THV. Eligibility was primarily decided by the heart team in accordance with 2021 European Society of Cardiology guidelines. As per the criteria of the third Valve Academic Research Consortium, the primary endpoint at 30 days was a composite of all-cause mortality, all stroke, bleeding (types 3 and 4), acute kidney injury (stages 2-4), major vascular complications, moderate or severe prosthetic valve regurgitation, and conduction system disturbances resulting in a permanent pacemaker implantation. Non-inferiority of the study device was tested in the intention-to-treat population using a non-inferiority margin of 10·44% and assuming an event rate of 26·10%. This trial is registered with ClinicalTrials.gov, NCT04275726, and EudraCT, 2020-000137-40, and is closed to new participants. Findings: Between Jan 6, 2021, and Dec 5, 2023, 768 participants with severe symptomatic native aortic stenosis were randomly assigned, 384 to the Myval THV and 384 to a contemporary THV. 369 (48%) participants had their sex recorded as female, and 399 (52%) as male. The mean age of participants was 80·0 years (SD 5·7) for those treated with the Myval THV and 80·4 years (5·4) for those treated with a contemporary THV. Median Society of Thoracic Surgeons scores were the same in both groups (Myval 2·6% [IQR 1·7-4·0] vs contemporary 2·6% [1·7-4·0]). The primary endpoint showed non-inferiority of the Myval (25%) compared with contemporary THV (27%), with a risk difference of -2·3% (one-sided upper 95% CI 3·8, pnon-inferiority<0·0001). No significant difference was seen in individual components of the primary composite endpoint. Interpretation: In individuals with severe symptomatic native aortic stenosis, the Myval THV met its primary endpoint at 30 days. Funding: Meril Life Sciences.